TransCode Therapeutics Inc RNAZ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RNAZ is a good fit for your portfolio.
News
-
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
-
TransCode Therapeutics Reports 2023 Results; Provides Business Update
-
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
-
Thinking about buying stock in Velo3D, Nova Lifestyle, indie Semiconductor, Citius Pharmaceuticals, or Transcode Therapeutics?
-
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
-
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
-
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
-
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
Trading Information
- Previous Close Price
- $0.44
- Day Range
- $0.45–0.46
- 52-Week Range
- $0.44–368.00
- Bid/Ask
- $0.45 / $0.46
- Market Cap
- $2.65 Mil
- Volume/Avg
- 118,519 / 441,200
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
Valuation
|
Metric
|
RNAZ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.17 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RNAZ
|
|---|---|
Quick Ratio | 0.79 |
Current Ratio | 1.28 |
Interest Coverage | −330.87 |
Quick Ratio
RNAZ
Profitability
|
Metric
|
RNAZ
|
|---|---|
Return on Assets (Normalized) | −254.07% |
Return on Equity (Normalized) | −783.26% |
Return on Invested Capital (Normalized) | −639.33% |
Return on Assets
RNAZ
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fdtgfqrq | Xvqlh | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ydqyvjt | Rzzvgt | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hgyxltsws | Ffhwm | $99.5 Bil | |
MRNA
| Moderna Inc | Wfjtvqkz | Zlt | $38.8 Bil | |
ARGX
| argenx SE ADR | Gddggtb | Thwx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Cvjpvvgym | Vms | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nwtvdrfc | Phfqmz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Glznzxzj | Wfscws | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kfbvkrnqp | Ghjqbj | $12.5 Bil | |
INCY
| Incyte Corp | Zvlhfwsgh | Pfwvcqd | $11.6 Bil |